Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a))

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 3, 2014, Pages 281-294

  Dallmeier, Dhayana ^a   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

apolipoprotein A1; apolipoprotein B; apolipoprotein B apolipoprotein A1; cardiovascular disease; high sensitive C reactive protein; lipoprotein(a); non HDL C

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHYLOMICRON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; LIPID; PLA2G7 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS (TOPIC); PARTICLE SIZE; PATHOGENESIS; PATIENT CARE; PERSONALIZED MEDICINE; PROTEIN BLOOD LEVEL; RISK MANAGEMENT; SECONDARY PREVENTION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; ADULT; BLOOD; COMPLICATION; DYSLIPIDEMIAS; PHYSIOLOGY; VASCULAR DISEASES;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; APOLIPOPROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DYSLIPIDEMIAS; HUMANS; LIPIDS; LIPOPROTEINS, LDL; PARTICLE SIZE; VASCULAR DISEASES;

EID: 84901378228     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.01.003     Document Type: Review

References (82)

1. K.D. Kochanek, J. Xu, and S.L. Murphy et al. Deaths: final data for 2009 Natl Vital Stat Rep 60 2011
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) J Am Med Assoc 285 2001 2486 2497
3. A.L. Catapano, Z. Reiner, and De Backer et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
4. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 151 2009 474 482
5. P. Greenland, J.S. Alpert, and G.A. Beller et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 103
6. S.M. Grundy, J.I. Cleeman, and C.N. Merz et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
7. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines Circulation 2013
8. L.G. Gilstrap, and T.J. Wang Biomarkers and cardiovascular risk assessment for primary prevention: an update Clin Chem 58 2012 72 82
9. M.H. Davidson Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure? J Am Coll Cardiol 60 2012 2616 2617
10. U.N. Khot, M.B. Khot, and C.T. Bajzer et al. Prevalence of conventional risk factors in patients with coronary heart disease J Am Med Assoc 290 2003 898 904
11. S.H. Shah, and J.A. de Lemos Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment J Am Med Assoc 302 2009 92 93
12. R.S. Vasan Biomarkers of cardiovascular disease: molecular basis and practical considerations Circulation 113 2006 2335 2362
13. O. Melander, C. Newton-Cheh, and P. Almgren et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community J Am Med Assoc 302 2009 49 57
14. S.M. Boekholdt, B.J. Arsenault, and S. Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis J Am Med Assoc 307 2012 1302 1309
15. J.D. Brunzell, M. Davidson, and C.D. Furberg et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
16. H.R. Superko Advanced lipoprotein testing and subfractionation are clinically useful Circulation 119 2009 2383 2395
17. S. Mora Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use Circulation 119 2009 2396 2404
18. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
19. J.G. Robinson What is the role of advanced lipoprotein analysis in practice? J Am Coll Cardiol 60 2012 2607 2615
20. J.B. Dube, M.B. Boffa, and R.A. Hegele et al. Lipoprotein(a): more interesting than ever after 50 years Curr Opin Lipidol 23 2012 133 140
21. J.G. Robinson, S. Wang, and B.J. Smith et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
22. A.D. Sniderman, J.C. Hogue, and J. Bergeron et al. Non-HDL cholesterol and apoB in dyslipidaemia Clin Sci (Lond) 114 2008 149 155
23. J.L. Witztum, and D. Steinberg Role of oxidized low density lipoprotein in atherogenesis J Clin Invest 88 1991 1785 1792
24. P. Duewell, H. Kono, and K.J. Rayner et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 464 2010 1357 1361
25. S.S. Martin, T.S. Metkus, and A. Horne et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations Am J Cardiol 110 2012 307 313
26. M.J. McQueen, S. Hawken, and X. Wang et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 2008 224 233
27. S.M. Grundy Use of emerging lipoprotein risk factors in assessment of cardiovascular risk J Am Med Assoc 307 2012 2540 2542
28. A. Zalewski, and C. Macphee Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target Arterioscler Thromb Vasc Biol 25 2005 923 931
29. H. Grallert, J. Dupuis, and J.C. Bis et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies Eur Heart J 33 2 2012 238 251
30. M.H. Davidson, M.A. Corson, and M.J. Alberts et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines Am J Cardiol 101 2008 51F 57F
31. E.R. Mohler 3rd, C.M. Ballantyne, and M.H. Davidson et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 2008 1632 1641
32. P.J. Barter, C.M. Ballantyne, and R. Carmena et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 259 2006 247 258
33. R.M. Krauss, and D.J. Burke Identification of multiple subclasses of plasma low density lipoproteins in normal humans J Lipid Res 23 1982 97 104
34. B. Lamarche, A. Tchernof, and S. Moorjani et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study Circulation 95 1997 69 75
35. S. Mora, M. Szklo, and J.D. Otvos et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 192 2007 211 217
36. G. Walldius, I. Jungner, and I. Holme et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
37. E. Di Angelantonio, N. Sarwar, and P. Perry et al. Major lipids, apolipoproteins, and risk of vascular disease J Am Med Assoc 302 2009 1993 2000
38. A.D. Sniderman, K. Williams, and J.H. Contois et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
39. E. Ingelsson, E.J. Schaefer, and J.H. Contois et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women J Am Med Assoc 298 2007 776 785
40. S. Erqou, S. Kaptoge, and P.L. Perry et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality J Am Med Assoc 302 2009 412 423
41. P.R. Kamstrup, M. Benn, and A. Tybjaerg-Hansen et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study Circulation 117 2008 176 184
42. S. Lamon-Fava, S.M. Marcovina, and J.J. Albers et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study J Lipid Res 52 2011 1181 1187
43. A. Gaw, H.M. Murray, and E.A. Brown Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER) Atherosclerosis 180 2005 381 388
44. R. Clarke, J.F. Peden, and J.C. Hopewell et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2009 2518 2528
45. P.R. Kamstrup, A. Tybjaerg-Hansen, and R. Steffensen et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction J Am Med Assoc 301 2009 2331 2339
46. G.R. Cooper, W.P.W.F., and G.L. Myers et al. Lipoprotein(a) and cardiovascular disease risk Laboratory Medicine Practice Guidelines. Emerging biomarkers for primary prevention of cardiovascular disease and stroke 2009 American Association for Clinical Chemistry, Inc. Washington, D.C. 29 34
47. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
48. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
49. ClinicalTrials.gov Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) 2013 NCT01764633
50. ClinicalTrials.gov Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727) (ODYSSEY outcomes) 2013 NCT01663402
51. Prevention, C.f.D.C.a. Center for Disease Control and Prevention's Lipid Standardization Program 2013 http://www.cdc.gov/labstandards/lsp.html
52. C.J. Packard, D.S. O'Reilly, and M.J. Caslake et al. Lipoprotein- associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group N Engl J Med 343 2000 1148 1155
53. W. Koenig, N. Khuseyinova, and H. Lowel et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany Circulation 110 2004 1903 1908
54. C.M. Ballantyne, R.C. Hoogeveen, and H. Bang et al. Lipoprotein- associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842
55. A. Thompson, P. Gao, and L. Orfei et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
56. I.J. Hatoum, N.R. Cook, and J.J. Nelson et al. Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women Am Heart J 161 2011 516 522
57. P.M. Ridker, J.G. MacFadyen, and R.L. Wolfert et al. Relationship of lipoprotein-associated phospholipase A(2) mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial Clin Chem 58 2012 877 886
58. ClinicalTrials.gov. The stabilization of ahterosclerotic plaque by initiation of darapladib therapy trial (stability), 2013. NCT00799903.
59. ClinicalTrials.gov. The stabilization of plaques using darapladib-thrombolysis in myocardial infarction 52 trial (SOLID-TIMI 52), 2013.
60. E. Di Angelantonio, P. Gao, and L. Pennells et al. Lipid-related markers and cardiovascular disease prediction J Am Med Assoc 307 2012 2499 2506
61. GlaxoSmithKline Press Release GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease 12 November 2013 London, UK
62. D. Thompson, M.B. Pepys, and S.P. Wood The physiological structure of human C-reactive protein and its complex with phosphocholine Structure 7 1999 169 177
63. M.B. Pepys, and G.M. Hirschfield C-reactive protein: a critical update J Clin Invest 111 2003 1805 1812
64. M. Miller, M. Zhan, and S. Havas High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey Arch Intern Med 165 2005 2063 2068
65. E. Braunwald Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials Eur Heart J 33 2012 430 432
66. D.I. Buckley, R. Fu, and M. Freeman et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med 151 2009 483 495
67. T.A. Pearson, G.A. Mensah, and R.W. Alexander et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
68. W. Koenig, H. Lowel, and J. Baumert et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany Circulation 109 2004 1349 1353
69. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
70. P.M. Ridker, J.J. Kastelein, and J. Genest et al. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care Eur Heart J 34 2013 1258 1261
71. S. Kaptoge, E. Di Angelantonio, and L. Pennells et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction N Engl J Med 367 2012 1310 1320
72. A.D. Sniderman, S. Islam, and S. Yusuf et al. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study Atherosclerosis 225 2012 444 449
73. P.M. Ridker, N. Rifai, and M.A. Pfeffer et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 1998 839 844
74. P.M. Ridker, C.P. Cannon, and D. Morrow et al. C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
75. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 2006 281 288
76. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
77. P.M. Ridker, W. Koenig, and J.J. Kastelein C-reactive protein in the Heart Protection Study Lancet 377 2011 1918 [author reply 1918-1919]
78. P.S. Sever, N.R. Poulter, and C.L. Chang et al. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial Eur Heart J 33 2012 486 494
79. J. Emberson, B. Derrick, and L. Emma et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study Lancet 377 2011 469 476
80. ClinicalTrials.gov. Cardiovascular risk reduction study (reduction in recurrent major CV disease events) (CANTOS), 2013. NCT01327846.
81. J.J. Kastelein, W.A. van der Steeg, and I. Holme et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
82. S. Mora, J. Buring, and P. Ridker Discordance of LDL Cholesterol with alternative LDL-related measures and future coronary events Circulation 2013 Dec 17. [Epub ahead of print]